You are here

P&T August 2014

Features

Health Care & Law
Part 1: Deconstructing Dispensing Errors

A comprehensive analysis of malpractice claims experience from a professional liability insurer, Healthcare Providers Service Organization, can help P&T committees better understand the risks and challenges they encounter each day.

A Number of Efforts Are Under Way to Reduce Price Pressure
Organizations are trying to address the high cost of “specialty” medications that treat conditions such as cancer, hepatitis C, and multiple sclerosis. While comprising less than 1% of U.S. prescriptions, these drugs now account for 27% of pharmacy spending.

Irritable bowel syndrome, a functional gastrointestinal disorder of uncertain pathophysiology, affects up to 55 million Americans. Medications available or in development include antispasmodics, antidepressants, and antidiarrheals.

Pipeline Plus

As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn’s disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.

Departments

Medication Errors
Verification of patient identity is needed at all stages.
Prescription: Washington
HHS adjusts its formulary “exception” policy for 2015.

FDA approvals, drug indications, and updates

Vedolizumab (Entyvio) for ulcerative colitis and Crohn’s disease; dalbavancin (Dalvance) for acute bacterial skin and skin structure infections; and antihemophilic factor, recombinant (Eloctate) for hemophilia A

Drug Forecast

Tedizolid phosphate: a second-generation oxazolidinone for acute bacterial skin and skin structure infections

Meeting Highlights

Attendees at the 19th Congress of the European Hematology Association in Milan, Italy, heard reports on new therapies for acute myeloid leukemia, chronic lymphocytic leukemia, β-thalassemia, multiple myeloma, and polycythemia vera.